Marco Carone

Marco Carone

Auto-generated profile, based on publicly available information

Marco Carone

Department of Biostatistics University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2017 in Biometrika
Verified
Journal Article
Closed access
DBD Benkeser
D Benkeser
MCM Carone
M Carone
MLM J Van Der Laan
M J Van Der Laan
PGPeter B. Gilbert
Peter B. Gilbert
Summary: Doubly robust estimators are widely used to draw inference about the average effect of a treatment. Such estimators are consistent for the effect of interest if either one of two nuisance parameters is consistently estimated. However, if flexible, data-adaptive estimators of these nuisance parameters are used, double robustness does not readily extend to inference. We present a general theoretical study of the behaviour of doubly robust estimators of an average treatment effect when one of the nuisance parameters is inconsistently estimated. We contrast different methods for constructing such estimators and investigate the extent to which they may be modified to also allow doubly robust inference. We find that while targeted minimum loss-based estimation can be used to solve this problem very naturally, common alternative frameworks appear to be inappropriate for this purpose. We provide a theoretical study and a numerical evaluation of the alternatives considered. Our simulations highlight the need for and usefulness of these approaches in practice, while our theoretical developments have broad implications for the construction of estimators that permit doubly robust inference in other problems.

11 October 2020 in Biometrics
Verified
Journal Article
Closed access
PDF file
BWBrian D. Williamson
Brian D. Williamson
PGPeter B. Gilbert
Peter B. Gilbert
MCMarco Carone
Marco Carone
NSNoah Simon
Noah Simon

5 January 2022 in Journal of the American Statistical Association
Verified
Journal Article
Closed access
BWBrian D. Williamson
Brian D. Williamson
PGPeter B. Gilbert
Peter B. Gilbert
NSNoah R. Simon
Noah R. Simon
MCMarco Carone
Marco Carone
In many applications, it is of interest to assess the relative contribution of features (or subsets of features) toward the goal of predicting a response—in other words, to gauge the variable importance of features. Most recent work on variable importance assessment has focused on describing the importance of features within the confines of a given prediction algorithm. However, such assessment does not necessarily characterize the prediction potential of features, and may provide a misleading reflection of the intrinsic value of these features. To address this limitation, we propose a general framework for nonparametric inference on interpretable algorithm-agnostic variable importance. We define variable importance as a population-level contrast between the oracle predictiveness of all available features versus all features except those under consideration. We propose a nonparametric efficient estimation procedure that allows the construction of valid confidence intervals, even when machine learning techniques are used. We also outline a valid strategy for testing the null importance hypothesis. Through simulations, we show that our proposal has good operating characteristics, and we illustrate its use with data from a study of an antibody against HIV-1 infection. Supplementary materials for this article are available online.

10 November 2022 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
YFYouyi Fong
Youyi Fong
AMAdrian B. McDermott
Adrian B. McDermott
DBDavid Benkeser
David Benkeser
SRSanne Roels
Sanne Roels
DSDaniel J. Stieh
Daniel J. Stieh
TTthe United States Government (USG)/CoVPN Biostatistics Team
the United States Government (USG)/CoVPN Biostatistics Team
Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4 weeks post vaccination as correlates of risk of moderate to severe-critical COVID-19 through 83 d post vaccination in the phase 3, double-blind placebo-controlled phase of ENSEMBLE, an international randomized efficacy trial of a single dose of Ad26.COV2.S. We also evaluated correlates of protection in the trial cohort. Of the three antibody immune markers we measured, we found most support for 50% inhibitory dilution (ID50) neutralizing antibody titre as a correlate of risk and of protection. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; P = 0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43%, 72%) at non-quantifiable ID50 (<2.7 IU50 ml−1) and increased to 89% (78%, 96%) at ID50 = 96.3 IU50 ml−1. Comparison of the vaccine efficacy by ID50 titre curves for ENSEMBLE-US, the COVE trial of the mRNA-1273 vaccine and the COV002-UK trial of the AZD1222 vaccine supported the ID50 titre as a correlate of protection across trials and vaccine types.

19 April 2023 in Science Translational Medicine
Verified
Journal Article
Open access
DBDavid Benkeser
David Benkeser
DMDavid C. Montefiori
David C. Montefiori
AMAdrian B. McDermott
Adrian B. McDermott
YFYouyi Fong
Youyi Fong
HJHolly E. Janes
Holly E. Janes
UTUnited States Government (USG)/CoVPN Biostatistics Teams
United States Government (USG)/CoVPN Biostatistics Teams
The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19 vaccine or placebo. We previously assessed IgG binding antibodies to the spike protein (spike IgG) or receptor binding domain (RBD IgG) and pseudovirus neutralizing antibody 50 or 80% inhibitory dilution titer measured on day 29 or day 57, as correlates of risk (CoRs) and CoPs against symptomatic COVID-19 over 4 months after dose. Here, we assessed a new marker, live virus 50% microneutralization titer (LV-MN 50 ), and compared and combined markers in multivariable analyses. LV-MN 50 was an inverse CoR, with a hazard ratio of 0.39 (95% confidence interval, 0.19 to 0.83) at day 29 and 0.51 (95% confidence interval, 0.25 to 1.04) at day 57 per 10-fold increase. In multivariable analyses, pseudovirus neutralization titers and anti-spike binding antibodies performed best as CoRs; combining antibody markers did not improve correlates. Pseudovirus neutralization titer was the strongest independent correlate in a multivariable model. Overall, these results supported pseudovirus neutralizing and binding antibody assays as CoRs and CoPs, with the live virus assay as a weaker correlate in this sample set. Day 29 markers performed as well as day 57 markers as CoPs, which could accelerate immunogenicity and immunobridging studies.

2 July 2017 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
DBDavid Benkeser
David Benkeser
MCMarco Carone
Marco Carone
PGPeter B. Gilbert
Peter B. Gilbert
Studying the incidence of rare events is both scientifically important and statistically challenging. When few events are observed, standard survival analysis estimators behave erratically, particularly if covariate adjustment is necessary. In these settings, it is possible to improve upon existing estimators by considering estimation in a bounded statistical model. This bounded model incorporates existing scientific knowledge about the incidence of an event in the population. Estimators that are guaranteed to agree with existing scientific knowledge on event incidence may exhibit superior behavior relative to estimators that ignore this knowledge. Focusing on the setting of competing risks, we propose estimators of cumulative incidence that are guaranteed to respect a bounded model and show that when few events are observed, the proposed estimators offer improvements over existing estimators in bias and variance. We illustrate the proposed estimators using data from a recent preventive HIV vaccine efficacy trial. Copyright © 2017 John Wiley & Sons, Ltd.